Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Bias
Cell Nucleus
/ drug effects
Cell Size
/ drug effects
Chromatin
/ chemistry
Chromosomal Proteins, Non-Histone
/ chemistry
DNA
/ metabolism
Escherichia coli
/ drug effects
Gene Expression Regulation, Bacterial
/ drug effects
Genome, Bacterial
/ drug effects
Humans
Loss of Function Mutation
Mutagenesis
Nucleosomes
/ chemistry
Oncogene Proteins
/ chemistry
Peptide Fragments
/ chemistry
Poly-ADP-Ribose Binding Proteins
/ chemistry
Protein Domains
/ genetics
Recombinant Proteins
/ chemistry
Toxicity Tests
/ methods
Escherichia coli
DEK
SAP domain
chromatin
oncogene
protein domain
protein function
recombinant protein toxicity
Journal
FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
02
02
2021
accepted:
26
02
2021
pubmed:
10
3
2021
medline:
16
7
2021
entrez:
9
3
2021
Statut:
ppublish
Résumé
The DEK oncoprotein regulates cellular chromatin function via a number of protein-protein interactions. However, the biological relevance of its unique pseudo-SAP/SAP-box domain, which transmits DNA modulating activities in vitro, remains largely speculative. As hypothesis-driven mutations failed to yield DNA-binding null (DBN) mutants, we combined random mutagenesis with the Bacterial Growth Inhibition Screen (BGIS) to overcome this bottleneck. Re-expression of a DEK-DBN mutant in newly established human DEK knockout cells failed to reduce the increase in nuclear size as compared to wild type, indicating roles for DEK-DNA interactions in cellular chromatin organization. Our results extend the functional roles of DEK in metazoan chromatin and highlight the predictive ability of recombinant protein toxicity in E. coli for unbiased studies of eukaryotic DNA modulating protein domains.
Identifiants
pubmed: 33686684
doi: 10.1002/1873-3468.14070
doi:
Substances chimiques
Chromatin
0
Chromosomal Proteins, Non-Histone
0
DEK protein, human
0
Nucleosomes
0
Oncogene Proteins
0
Peptide Fragments
0
Poly-ADP-Ribose Binding Proteins
0
Recombinant Proteins
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1438-1453Informations de copyright
© 2021 Federation of European Biochemical Societies.
Références
Kappes F, Scholten I, Richter N, Gruss C and Waldmann T (2004) Functional domains of the ubiquitous chromatin protein DEK. Mol Cell Biol 24, 6000-6010.
Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA and Gruss C (2004) Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 24, 6011-6020.
Waldmann T, Scholten I, Kappes F, Hu HG and Knippers R (2004) The DEK protein-an abundant and ubiquitous constituent of mammalian chromatin. Gene 343, 1-9.
Waldmann T, Baack M, Richter N and Gruss C (2003) Structure-specific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 31, 7003-7010.
Kappes F, Burger K, Baack M, Fackelmayer FO and Gruss C (2001) Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 276, 26317-26323.
Waidmann S, Kusenda B, Mayerhofer J, Mechtler K and Jonak C (2014) A DEK domain-containing protein modulates chromatin structure and function in Arabidopsis. Plant Cell 26, 4328-4344.
von Lindern M, Breems D, van Baal S, Adriaansen H and Grosveld G (1992) Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 5, 227-234.
Dong X, Michelis MA, Wang J, Bose R, DeLange T and Reeves WH (1998) Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum 41, 1505-1510.
Murray KJ, Szer W, Grom AA, Donnelly P, Levinson JE, Giannini EH, Glass DN and Szer IS (1997) Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol 24, 560-567.
Szer IS, Sierakowska H and Szer W (1994) A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J Rheumatol 21, 2136-2142.
Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A et al., (2007) Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 5, 881-890.
Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M and Muller H (2006) DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5, 1202-1207.
Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R and Lin Z (2009) Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int 59, 443-447.
Kondoh N et al., (1999) Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 59, 4990-4996.
Kroes RA et al., (2000) The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 156, 191-198.
Orlic M, Spencer CE, Wang L and Gallie BL (2006) Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 45, 72-82.
Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G and Cordon-Cardo C (2003) Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 163, 505-516.
Riveiro-Falkenbach E and Soengas MS (2010) Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 16, 2932-2938.
Oancea C, Ruster B, Henschler R, Puccetti E and Ruthardt M (2010) The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 24, 1910-1919.
Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A et al., (2005) Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 24, 6441-6449.
Mor-Vaknin N, Saha A, Legendre M, Carmona-Rivera C, Amin MA, Rabquer BJ, Gonzales-Hernandez MJ, Jorns J, Mohan S, Yalavarthi S et al., (2017) DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nat Commun 8, 14252.
Capitano ML and Broxmeyer HE (2017) A role for intracellular and extracellular DEK in regulating hematopoiesis. Curr Opin Hematol 24, 300-306.
Smith EA, Gole B, Willis NA, Soria R, Starnes LM, Krumpelbeck EF, Jegga AG, Ali AM, Guo H, Meetei AR et al., (2017) DEK is required for homologous recombination repair of DNA breaks. Sci Rep 7, 44662.
Xu X, Zou L, Yao Q, Zhang Y, Gan L and Tang L (2017) Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3beta/p-Tyr216-GSK-3beta/beta-catenin axis. Oncol Rep 38, 1035-1042.
Deutzmann A, Ganz M, Schonenberger F, Vervoorts J, Kappes F and Ferrando-May E (2015) The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress. Oncogene 34, 4270-4277.
Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu ZJ and Zhang ZY (2015) Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma. Mol Med Rep 11, 1318-1323.
Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A et al., (2015) Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget 6, 1806-1820.
Sanden C and Gullberg U (2015) The DEK oncoprotein and its emerging roles in gene regulation. Leukemia 29, 1632-1636.
Matrka MC, Hennigan RF, Kappes F, DeLay ML, Lambert PF, Aronow BJ and Wells SI (2015) DEK over-expression promotes mitotic defects and micronucleus formation. Cell Cycle 14, 3939-3953.
Adams AK, Bolanos LC, Dexheimer PJ, Karns RA, Aronow BJ, Komurov K, Jegga AG, Casper KA, Patil YJ, Wilson KM et al., (2015) IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Oncotarget 6, 43395-43407.
Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison Ml et al., (2015) DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. Oncogene 34, 868-877.
Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE and Wells SI (2015) The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene 34, 2325-2336.
Saha AK, Kappes F, Mundade A, Deutzmann A, Rosmarin DM, Legendre M, Chatain N, Al-Obaidi Z, Adams BS, Ploegh Hl et al., (2013) Intercellular trafficking of the nuclear oncoprotein DEK. Proc Natl Acad Sci U S A 110, 6847-6852.
Broxmeyer HE, Kappes F, Mor-Vaknin N, Legendre M, Kinzfogl J, Cooper S, Hangoc G and Markovitz DM (2012) DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev 21, 1449-1454.
Mor-Vaknin N, Kappes F, Dick AE, Legendre M, Damoc C, Teitz-Tennenbaum S, Kwok R, Ferrando-May E, Adams BS and Markovitz DM (2011) DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum 63, 556-567.
Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF et al., (2009) DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol 174, 71-81.
Wise-Draper TM et al., (2009) Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 69, 1792-1799.
Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K and Wells SI (2005) The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 79, 14309-14317.
Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE and Wells SI (2011) The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 30, 2741-2752.
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM et al., (2011) The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 39, 7465-7476.
Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DSL, Chinnaiyan AM, Markovitz DM and Soengas MS (2009) Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 69, 6405-6413.
Karam M, Thenoz M, Capraro V, Robin J-P, Pinatel C, Lançon A, Galia P, Sibon D, Thomas X, Ducastelle-Lepretre S et al., (2014) Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. Neoplasia 16, 21-30.
Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R et al., (2011) The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 25, 673-678.
Sawatsubashi S, Murata T, Lim J, Fujiki R, Ito S, Suzuki E, Tanabe M, Zhao Y, Kimura S, Fujiyama S et al., (2010) A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev 24, 159-170.
Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I et al., (2010) DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 29, 4671-4681.
Takata H, Nishijima H, Ogura S, Sakaguchi T, Bubulya PA, Mochizuki T and Shibahara K (2009) Proteome analysis of human nuclear insoluble fractions. Genes Cells 14, 975-990.
Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM and Ferrando-May E (2008) DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 28, 3245-3257.
Gamble MJ and Fisher RP (2007) SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 14, 548-555.
Ko SI, Lee I-S, Kim J-Y, Kim S-M, Kim D-W, Lee K-S, Woo K-M, Baek J-H, Choo J-K and Seo S-B (2006) Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK. FEBS Lett 580, 3217-3222.
Tabbert A, Kappes F, Knippers R, Kellermann J, Lottspeich F and Ferrando-May E (2006) Hypophosphorylation of the architectural chromatin protein DEK in death-receptor-induced apoptosis revealed by the isotope coded protein label proteomic platform. Proteomics 6, 5758-5772.
Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D (2006) The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 26, 9484-9496.
Soares LM, Zanier K, Mackereth C, Sattler M and Valcarcel J (2006) Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. Science 312, 1961-1965.
Bohm F, Kappes F, Scholten I, Richter N, Matsuo H, Knippers R and Waldmann T (2005) The SAF-box domain of chromatin protein DEK. Nucleic Acids Res 33, 1101-1110.
Cleary J, Sitwala KV, Khodadoust MS, Kwok RP, Mor-Vaknin N, Cebrat M, Cole PA and Markovitz DM (2005) p300/CBP-associated factor drives DEK into interchromatin granule clusters. J Biol Chem 280, 31760-31767.
Hollenbach AD, McPherson CJ, Mientjes EJ, Iyengar R and Grosveld G (2002) Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J Cell Sci 115, 3319-3330.
Le Hir H, Gatfield D, Izaurralde E and Moore MJ (2001) The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. Embo J 20, 4987-4997.
Dong X, Wang J, Kabir FN, Shaw M, Reed AM, Stein L, Andrade LEC, Trevisani VFM, Miller ML, Fujii T et al., (2000) Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis Rheum 43, 85-93.
Wichmann I, Respaldiza N, Garcia-Lozano JR, Montes M, Sanchez-Roman J and Nunez-Roldan A (2000) Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE). Clin Exp Immunol 119, 530-532.
Fornerod M, Boer J, van Baal S, Morreau H and Grosveld G (1996) Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN. Oncogene 13, 1801-1808.
Sierakowska H, Williams KR, Szer IS and Szer W (1993) The putative oncoprotein DEK, part of a chimera protein associated with acute myeloid leukaemia, is an autoantigen in juvenile rheumatoid arthritis. Clin Exp Immunol 94, 435-439.
Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G and Ashburner BP (2006) Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 281, 26802-26812.
Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H and Wells SI (2006) Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 26, 7506-7519.
Fu GK, Grosveld G and Markovitz DM (1997) DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci U S A 94, 1811-1815.
Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R and Gruss C (2000) The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the replication efficiency of DNA replication in a chromatin-specific manner. Genes & Developm 14, 1308-1312.
Cheung TH, Quach NL, Charville GW, Liu L, Park L, Edalati A, Yoo B, Hoang P and Rando TA (2012) Maintenance of muscle stem-cell quiescence by microRNA-489. Nature 482, 524-528.
Waldmann T, Eckerich C, Baack M and Gruss C (2002) The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 277, 24988-24994.
Matrka MC, Watanabe M, Muraleedharan R, Lambert PF, Lane AN, Romick-Rosendale LE and Wells SI (2017) Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PLoS One 12, e0177952.
Ivanauskiene K, Delbarre E, McGhie JD, Kuntziger T, Wong LH and Collas P (2014) The PML-associated protein DEK regulates the balance of H3.3 loading on chromatin and is important for telomere integrity. Genome Res 24, 1584-1594.
Cavellan E, Asp P, Percipalle P and Farrants AK (2006) The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear proteins in transcription. J Biol Chem 281, 16264-16271.
Privette Vinnedge LM, Kappes F, Nassar N and Wells SI (2013) Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle 12, 51-66.
Aravind L and Koonin EV (2000) SAP - a putative DNA-binding motif involved in chromosomal organization. Trends Biochem Sci 25, 112-114.
Kipp M, Gohring F, Ostendorp T, van Drunen CM, van Driel R, Przybylski M and Fackelmayer FO (2000) SAF-Box, a conserved protein domain that specifically recognizes scaffold attachment region DNA [In Process Citation]. Mol Cell Biol 20, 7480-7489.
Devany M, Kappes F, Chen KM, Markovitz DM and Matsuo H (2008) Solution NMR structure of the N-terminal domain of the human DEK protein. Protein Sci 17, 205-215.
Zlatanova J, Seebart C and Tomschik M (2008) The linker-protein network: control of nucleosomal DNA accessibility. Trends Biochem Sci 33, 247-253.
Brazda V, Laister RC, Jagelska EB and Arrowsmith C (2011) Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol Biol 12, 33.
Guo H, Xu N, Prell M, Königs H, Hermanns-Sachweh B, Lüscher B and Kappes F (2021) Bacterial Growth Inhibition Screen (BGIS): harnessing recombinant protein toxicity for rapid and unbiased interrogation of protein function. FEBS Lett 595, 1422-1437.
Thomas JO and Stott K (2012) H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans 40, 341-346.
Luscombe NM and Thornton JM (2002) Protein-DNA interactions: amino acid conservation and the effects of mutations on binding specificity. J Mol Biol 320, 991-1009.
Baker CM and Grant GH (2007) Role of aromatic amino acids in protein-nucleic acid recognition. Biopolymers 85, 456-470.
Parkinson G, Gunasekera A, Vojtechovsky J, Zhang X, Kunkel TA, Berman H and Ebright RH (1996) Aromatic hydrogen bond in sequence-specific protein DNA recognition. Nat Struct Biol 3, 837-841.
Lejeune D, Delsaux N, Charloteaux B, Thomas A and Brasseur R (2005) Protein-nucleic acid recognition: statistical analysis of atomic interactions and influence of DNA structure. Proteins 61, 258-271.
Rohs R, West SM, Sosinsky A, Liu P, Mann RS and Honig B (2009) The role of DNA shape in protein-DNA recognition. Nature 461, 1248-1253.
Fahrer J, Popp O, Malanga M, Beneke S, Markovitz DM, Ferrando-May E, Burkle A and Kappes F (2010) High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length. Biochemistry 49, 7119-7130.
Luscombe NM, Laskowski RA and Thornton JM (2001) Amino acid-base interactions: a three-dimensional analysis of protein-DNA interactions at an atomic level. Nucleic Acids Res 29, 2860-2874.
Kirchler T, Briesemeister S, Singer M, Schütze K, Keinath M, Kohlbacher O, Vicente-Carbajosa J, Teige M, Harter K and Chaban C (2010) The role of phosphorylatable serine residues in the DNA-binding domain of Arabidopsis bZIP transcription factors. Eur J Cell Biol 89, 175-183.
Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403, 41-45.
Bartke T and Kouzarides T (2011) Decoding the chromatin modification landscape. Cell Cycle 10, 182.